Outcome of Board Meeting held on May 18, 2026
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Strides Pharma Science Limited's Board approved audited consolidated financial results for Q4 and FY ended March 31, 2026. Total revenue for FY2026 grew to Rs. 50,094 million from Rs. 46,241 million in FY2025, an increase of about 8.3%. Profit after tax from continuing operations increased significantly to Rs. 5,745 million from Rs. 4,094 million, representing a 40.3% year-on-year growth. Basic EPS improved to Rs. 60.34 from Rs. 44.05. The Board recommended a final dividend of Rs. 5 per equity share (50% payout). The statutory auditor B S R & Co. LLP issued an unmodified (clean) opinion. Exceptional items recorded during the year include product recall expenses and impairment charges totaling Rs. 268 million. The company completed a demerger of its CDMO and Soft Gelatin business in November 2024 and sold investment property for Rs. 1,129 million during Q3 FY2026.
Strong profit growth of 40% with clean audit opinion signals healthy operations. The dividend recommendation and positive cash flow from operations (Rs. 7,025 million) are positive signals for shareholders. Exceptional items related to product recalls require monitoring but appear adequately provided for.